换一批Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
第一作者：
Robert,Roskoski
第一单位：
Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 106, Box 19 Horse Shoe, NC 28742-8814, United States. Electronic address: rrj@brimr.org.
作者：
关键词
3-diaryl-1?H-pyrazol-4-yl)hydantoin5-(1ATP-binding siteAsciminib (PubChem CID: 72165228)Bosutinib (PubChem CID: 5328940)Dasatinib (PubChem CID: 3062316)GNF-2 (PubChem CID: 5311510)GNF-5 (PubChem CID: 44129660)Imatinib (PubChem CID: 5291)Myristate (PubChem CID: 11005)Myristate-binding siteNilotinib (PubChem CID: 644241)Ponatinib (PubChem CID: 24826799)Protein kinase inhibitor classificationProtein kinase structureRegulation of Abl-1b enzyme activitySpecifically targeting the ABL myristoyl pocketor DPH (PubChem CID: 660311)
医学主题词
抗肿瘤药(Antineoplastic Agents);抗药性, 肿瘤(Drug Resistance, Neoplasm);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);人类(Humans);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);费城染色体(Philadelphia Chromosome);蛋白激酶抑制剂(Protein Kinase Inhibitors)
DOI
10.1016/j.phrs.2022.106156
PMID
35257901
发布时间
2022-05-05
- 浏览1
Pharmacological research
106156页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
